SCHEMBL1574438

SCHEMBL1574438

CCCN(CCC)C1CN(C(=O)Nc2cccc(SC)c2)C1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.57
KMT2A Q03164 3/20 0.51
MEN1 O00255 2/20 0.51
SMN1; SMN2 Q16637 4/20 0.48
GAA P10253 1/20 0.47
LMNA P02545 2/20 0.46
UBE2M P61081 1/20 0.46
DCUN1D1 Q96GG9 1/20 0.46
ALDH1A1 P00352 2/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C9 P11712 1/20 0.46
HPGD P15428 1/20 0.46
CYP2C19 P33261 1/20 0.46
POLB P06746 2/20 0.46
TP53 P04637 1/20 0.46
MAPK1 P28482 1/20 0.46
HSD17B10 Q99714 1/20 0.46
KDM4E B2RXH2 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1575079 0.91 MAPT (0.57) MAPTKMT2AMEN1SMN1; SMN2GAA
SCHEMBL1575006 0.91 MAPT (0.59) MAPTKMT2AMEN1SMN1; SMN2GAA
SCHEMBL1574553 0.86 MAPT (0.52) MAPTKMT2AMEN1SMN1; SMN2GAA
SCHEMBL1575726 0.85 MAPT (0.56) MAPTKMT2AMEN1SMN1; SMN2GAA
SCHEMBL1573940 0.85 ALDH1A1 (0.56) MAPTKMT2AMEN1SMN1; SMN2GAA
SCHEMBL1575307 0.84 MAPT (0.63) MAPTKMT2AMEN1SMN1; SMN2GAA
SCHEMBL1575364 0.84 CYP2D6 (0.50) MAPTKMT2AMEN1SMN1; SMN2LMNA
SCHEMBL1574779 0.84 NPSR1 (0.55) MAPTKMT2AMEN1SMN1; SMN2ALDH1A1
SCHEMBL1574781 0.83 GRIN2B (0.50) MAPTSMN1; SMN2ALDH1A1CYP2C9HPGD
SCHEMBL1574907 0.82 GRIN2B (0.57) MAPTKMT2AMEN1GAALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2308562-A2 Azetidine ring compounds and drugs comprising the same Ono Pharmaceutical Co., Ltd. (JP) 2011-04-13 EP disclosed
US-7511159-B2 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO., LTD. (JP) 2009-03-31 US disclosed
US-20070135402-A1 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO., LTD. (JP) 2007-06-14 US disclosed
EP-1698375-A1 AZETIDINE RING COMPOUNDS AND DRUGS COMPRISING THE SAME ONO PHARMACEUTICAL CO., LTD. (JP) 2006-09-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135402-A1 Azetidine ring compounds and drugs comprising the same EDNRA, LIPG, EDNRB MAPT 3908/4885KMT2A 2539/4885MEN1 1113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.